Anti-CD40 antibodies and uses thereof
AssigneesBristol-Myers Squibb Company, CytomX Therapeutics, Inc.
InventorsBryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
Life of this patent
Estimating the term…
Abstract
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Claims20
A nucleic acid molecule encoding a heavy chain variable region (VH) and Worn a light chain variable region (VL) of an antibody, or antigen binding portion thereof, that specifically binds to a human CD40, wherein:
- (a) the VH comprises the amino acid sequence of SEQ ID NO:
- 54;
- and
- (b) the VL comprises the amino acid sequence selected from the group consisting of residues 1-112 of SEQ ID NO:
- 6, 8, and 10.
A nucleic acid molecule, encoding a heavy chain variable region (VH) and a light chain variable region (VL) of an antibody, or antigen binding portion thereof, that specifically binds to human CD40, wherein the VH comprises a CDR1, CDR2, and CDR3 and the VL comprises a CDR1, CDR2, and CDR3, and wherein:
- (a) the CDR1 of the VH comprises the amino acid sequence GYNMN (SEQ ID NO:
- 55), the CDR2 of the VH comprises the amino acid sequence NIDPYYGNTNYNQKFKG (SEQ ID NO:
- 56), and the CDR3 of the VH comprises the amino acid sequence LGLQLYALDY (SEQ ID NO:
- 58);
- and
- (b) the CDR1 of the VL comprises the amino acid sequence RASQSLVHSNANTYLH (SEQ ID NO:
- 63), the CDR2 of the VL comprises the amino acid sequence KLTNRFF (SEQ ID NO:
- 64), and the CDR3 of the VL comprises the amino acid sequence QQSIHVPWT (SEQ ID NO:
- 66).
Dependencies are inferred from the claim text.